HCG launches Radixact X9 – the new generation TomoTherapy in India

The Radixact System is being used at HCG EKO cancer centre, a partnership between HCG, India’s largest provider of Cancer care and EKO X-Ray & Imaging Institute, a Premier Institute of Diagnosis in Kolkata

0
46
Download PDF
Image for representational purpose only.

Kolkata: HealthCare Global Enterprises (HCG), India’s largest provider of cancer care has brought first Radixact X9 – the new generation TomoTherapy in India to treat cancer patients.

The Radixact System is being used at HCG EKO cancer centre, a partnership between HCG, India’s largest provider of Cancer care and EKO X-Ray and Imaging Institute, a premier institute of diagnosis, not just in Kolkata, but also across the nation that marks a major step forward in cancer treatment through precision, speed, efficiency and ease of use with the potential to provide significant clinical benefits to cancer patients in India.

An early adopter of leading-edge technology, HCG – the specialist in cancer care was among the first in India to introduce the TomoH System, a fully integrated 3D conformal and image-guided intensity-modulated radiation therapy (IG-IMRT) system, and the CyberKnife Robotic Radiosurgery System, technology designed to deliver stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).

Dr B S Ajaikumar, Chairman and CEO, Healthcare Global Enterprises (HCG) Enterprises Ltd said, “Being at the forefront of the fight against cancer, HCG strives to offer precision treatment to cancer patients, reinforcing the ideology – the right way, the first time.  The practice of adopting cutting-edge technologies like the Radixact X9 – the new generation TomoTherapy, along with our clinical expertise, has enabled us to move one step closer towards precise and personalized care, therefore improving the quality of life of cancer patients. Introducing the Radixact in Kolkata is to ensure that advance care is accessible by the patients of West Bengal and the neighboring states, and they don’t have to travel to far off locations, away from their home and close ones for cancer treatment.”

Dr Ayan Basu, Head of Radiation Oncology, HCG EKO Cancer Centre said, “Radixact now enables us to accurately deliver higher doses incorporating functional imaging like PET, improving chances of cure. The addition of India’s first Radixact X9 – the new generation TomoTherapy to HCG EKO gives our patients and radiotherapy team several key advantages: quick, accurate, daily CT scan guided, adaptable, highly conformal radiotherapy which gives the oncologist confidence to accurately treat all sites and cancer types. To share an instance, the inbuilt CT scan imaging in a Radixact system allows treating Bone Marrow Transplant patients accurately to the complete bone marrow instead of exposing all internal organs. One of the unique advantages of the system is for children with medulloblastoma (which constitutes one fifth of all childhood brain tumors), where the child can comfortably lie on his/her back and the radiation beam treats more than three times the length possible in regular machines in a single movement of the treatment couch. Radixact is both versatile and comprehensive.”

Present at event, Dr S K Sharma, Chairman, EKO X-Ray & Imaging Institute, “The thought behind HCG EKO collaboration is the common driving force of the two entities, which is to constantly upgrade the practice with aid of new and advanced technologies. Combining the two respective specialties, that is, diagnostic services by EKO and cancer treatment and care by HCG, the aim is to provide comprehensive facilities that cater the need for advanced cancer treatment and care all under one roof. This is further strengthened by having a production unit of cancer detection medicine (FDG) at same premises. In the endeavour for creating a centre of excellence in cancer care, HCG EKO Kolkata proudly introduces Radixact System for the first time in India. This shall benefit thousands of cancer patients of West Bengal and rest of eastern region by providing HCG’s unparalleled expertise and accurate radiation treatment.”

http://cancerindia.org.in/wp-content/uploads/2017/12/imp.jpgAccording to data from the International Agency for Research on Cancer’s GLOBOCAN initiative, the number of new cases of cancer diagnosed in India will grow from approximately 1 million per year in 2012 to more than 1.5 million by 2030. As per NICPR data, West Bengal and neighboring states have the leading cases of head and neck, oral, stomach, and lung, urinary bladder cancers due to factors like tobacco usage, air and water pollution. To address the growing demand of holistic cancer care in the region, introduction of innovative technology like Radixact will provide the patients access to comprehensive care.